Activities

August 2025

46th Annual Conference of the International Society for Clinical Biostatistics - Basel, Switzerland

• Izem R, Rebora P, Bakewell N, Gail MH, Cadarette SM: Mission impossible? Specifying target estimands for long-term risks and benefits of novel therapies. Oral Presentation.

Joint Statistical Meeting - Nashville, Tennessee, USA

• Bakewell N, [On Behalf of Topic Group 5 (Study Design)]: On some contributions of STRATOS Topic Group 5 on Study Design: Guidance for the design of observational studies to estimate the effects of long-term drug exposures on safety outcomes. Oral Presentation.

September 2024

3rd STRATOS Workshop - Leiden, Netherlands

• Bakewell N, Burden AM, Hayes KN, Stukel TA, Cadarette SM. Guidance for the design of observational studies to estimate the effects of long-term drug exposures. Poster presentation, STRATOS Workshop.

August 2024

40th Annual Meeting, International  Society for Pharmacoepidemiology - Berlin, Germany

• Bakewell N, Burden AM, Hayes KN, Stukel TA, Cadarette SM: Guidance for the Design of Observational Studies to Estimate the Effects of Long-term Drug Exposures [abstract]. Pharmacoepidemiol Drug Saf 2024; 33(S2):609-610. Poster Presentation.

November 2021 

Virtual STRATOS meeting, day 1. 

• Mitch Gail, Update and activities of topic group 5 (design) and potential collaborations with other STRATOS topic groups.

June 2019 

Toward a Comprehensive, Integrated Framework for Advanced Statistical Analyses of Observational Studies, Banff AB, Canada. 

• Mitch Gail, Potential collaborations between study design topic group (TG5) and other STRATOS topic groups.

September 2017 

German Association for Medical Informatics, Biometry & Epidemiology - Oldenburg, Germany.

• Peggy Sekula, Design of observational studies and the need for guidance – prognostic studies as an example, abstract page 68.

August 2017 

International Biometric Society Joint Conference on Biometrics & Biopharmaceutical Statistics, Central European Network, Vienna, Austria. 

• Doug Altman on behalf of STRATOS TG5, Study design issues in popular designs for observational studies.

• Peggy Sekula on behalf of STRATOS TG5, Prognostic studies and the need for guidance.